- Home
- SNGX vs RNAZ Comparison
SNGX vs RNAZ Comparison
Compare SNGX & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- RNAZ
- Stock Information
- Founded
- SNGX 1987
- RNAZ 2016
- Country
- SNGX United States
- RNAZ United States
- Employees
- SNGX N/A
- RNAZ N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- RNAZ Health Care
- Exchange
- SNGX Nasdaq
- RNAZ Nasdaq
- Market Cap
- SNGX 10.1M
- RNAZ 8.7M
- IPO Year
- SNGX 1987
- RNAZ 2021
- Fundamental
- Price
- SNGX $1.64
- RNAZ $15.16
- Analyst Decision
- SNGX Strong Buy
- RNAZ Strong Buy
- Analyst Count
- SNGX 1
- RNAZ 1
- Target Price
- SNGX $6.00
- RNAZ $280.00
- AVG Volume (30 Days)
- SNGX 2.9M
- RNAZ 413.5K
- Earning Date
- SNGX 11-07-2025
- RNAZ 11-13-2025
- Dividend Yield
- SNGX N/A
- RNAZ N/A
- EPS Growth
- SNGX N/A
- RNAZ N/A
- EPS
- SNGX N/A
- RNAZ N/A
- Revenue
- SNGX N/A
- RNAZ N/A
- Revenue This Year
- SNGX N/A
- RNAZ N/A
- Revenue Next Year
- SNGX N/A
- RNAZ N/A
- P/E Ratio
- SNGX N/A
- RNAZ N/A
- Revenue Growth
- SNGX N/A
- RNAZ N/A
- 52 Week Low
- SNGX $1.09
- RNAZ $6.15
- 52 Week High
- SNGX $6.23
- RNAZ $720.72
- Technical
- Relative Strength Index (RSI)
- SNGX 41.70
- RNAZ 69.62
- Support Level
- SNGX $1.60
- RNAZ $13.45
- Resistance Level
- SNGX $1.97
- RNAZ $15.90
- Average True Range (ATR)
- SNGX 0.16
- RNAZ 1.60
- MACD
- SNGX 0.06
- RNAZ 0.37
- Stochastic Oscillator
- SNGX 61.63
- RNAZ 47.60
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.